GKB Ophthalmics (533212)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Latest quarter turned profitable with ₹57 Cr sales and ₹1 Cr net profit.
• Sales growth of 120% and profit growth of 121.67% show recent operating momentum.
• Piotroski F-Score of 6/9 suggests some fundamental improvements underway.
• Market cap of only ₹53 Cr leaves room for a meaningful re-rating if the turnaround sustains.

Concerns

• ROE of -20.35% and ROCE of -6.00% indicate the business is destroying capital.
• P/E of 0.00 reflects no meaningful trailing earnings despite one profitable quarter.
• P/B of 2.46 against a book value of ₹42.65 offers no margin of safety at ₹104.90.
• No dividend, no debt/equity data, and no promoter holding disclosure limit a proper balance sheet check.

AI Analysis

Let me examine GKB Ophthalmics as I would any business. At ₹104.90, the market values this medical equipment supplier at only ₹53 crore. The latest quarter shows ₹57 crore revenue and ₹1 crore net profit, so there is some recent life. But the full picture is troubling. The company is earning a return on equity of -20.35% and a return on capital of -6.00%. In other words, shareholders' money is being destroyed. Book value is ₹42.65, so I am being asked to pay ₹104.90, or 2.46 times book, for a business whose profitability is negative. That is not a margin of safety; that is paying up for hope. Reported sales growth of 120% and profit growth of 121.67% look spectacular, but when the base is weak, percentage recoveries can mislead. The P/E is zero or blank because trailing earnings are not meaningful. There is no dividend to compensate while waiting. I also have no debt/equity or promoter holding data, which makes a thorough Graham-style balance sheet audit impossible. The Piotroski score of 6/9 is neither terrible nor compelling; it hints at improving operations, but a single quarter's net profit of ₹1 crore on ₹57 crore of sales is a very thin margin. Is this a wonderful business? No. Is there a durable competitive moat? I do not see it from these numbers. GKB may be a turnaround candidate, but a turn must prove itself over multiple quarters with rising return on capital and a clean balance sheet. Until then, the prudent course is to watch, not buy. Price is what you pay; value is what you get—and here the value is not yet visible.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer